Skip to main content

Advertisement

SpringerLink
Log in

Diagnostic Value of HE4 in Distinguishing Malignant from Benign Pelvic Masses

  • Original Paper
  • Published:
Indian Journal of Gynecologic Oncology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the diagnostic value of HE4 for distinguishing malignant pelvic masses from benign ones.

Methods

Eighty-five female patients diagnosed with pelvic masses and underwent elective surgery were enrolled. Preoperative serum samples for CA125, ROMA and HE4 were obtained, and the values were calculated. The diagnostic performances of HE4, CA-125 and ROMA, and best cutoff points were evaluated by using receiver operating characteristics curves and calculating sensitivity, specificity and area under curve (AUC).

Results

Among 85 women (47 premenopausal and 38 postmenopausal), 23 patients were diagnose with malignant pelvic masses while 62 were with benign. Significant diagnostic performance in discriminating malignant masses from benign ones and best cutoff points for CA125: premenopause, specificity 92.3 %, sensitivity 100 %, AUC ≥0.981, best cutoff >95.5, postmenopause, specificity 82.6 %, sensitivity 100 %, AUC ≥0.941, best cutoff point >58.15; for ROMA: postmenopause, specificity 73.9 %, sensitivity 100 %, AUC ≥0.904, best cutoff point >28.91. There was no significant value of HE4 alone in differentiation of pre–post menopausal benign and malignant groups (p = 0.910, p = 0.347).

Conclusions

HE4 may have more diagnostic value when used in combination with other biomarkers in differential diagnosis of malignant pelvic masses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:359–86.

    Article  Google Scholar 

  2. Yang Z, Luo Z, Zhao B, Zhang W, Zhang J, Li Z, et al. Diagnosis and preoperative predictive value of serum HE4 concentrations for optimal debulking in epithelial ovarian cancer. Oncol Lett. 2013;6:28–34.

    PubMed  PubMed Central  Google Scholar 

  3. Kristjansdottir B, Levan K, Partheen K, Sundfeldt K. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer. Gynecol Oncol. 2013;131:52–8.

    Article  CAS  PubMed  Google Scholar 

  4. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol. 1990;97:922–9.

    Article  CAS  PubMed  Google Scholar 

  5. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112:40–6.

    Article  CAS  PubMed  Google Scholar 

  6. Abraham J. OVA1 test for preoperative assessment of ovarian cancer. Community Oncol. 2010;27:249–51.

    Article  Google Scholar 

  7. Nunes N, Yazbek J, Ambler G, Hoo W, Naftalin J, Jurkovic D. Prospective evaluation of the IOTA logistic regression model LR2 for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol. 2012;40:355–9.

    Article  CAS  PubMed  Google Scholar 

  8. Yanaranop M, Tiyayon J, Siricharoenthai S, Nakrangsee S, Thinkhamrop B. Rajavithi-ovarian cancer predictive score (R-OPS): a new scoring system for predicting ovarian malignancy in women presenting with a pelvic mass. Gynecol Oncol. 2016;141:479–84.

    Article  PubMed  Google Scholar 

  9. Zhang P, Wang C, Cheng L, Zhang P, Guo L, Liu W, et al. Development of a multi-marker model combining HE4, CA125, progesterone, and estradiol for distinguishing benign from malignant pelvic masses in postmenopausal women. Tumour Biol. 2016;37:2183–91.

    Article  CAS  PubMed  Google Scholar 

  10. Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol. 2010;203:228.e1–6.

    Article  Google Scholar 

  11. Karlsen MA, Sandhu N, Høgdall C, Christensen IJ, Nedergaard L, Lundvall L, et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2012;127:379–83.

    Article  PubMed  Google Scholar 

  12. Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati M, et al. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med. 2011;49:521–5.

    Article  CAS  PubMed  Google Scholar 

  13. Jacob F, Meier M, Caduff R, Goldstein D, Pochechueva T, Hacker N, et al. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol. 2011;121:487–91.

    Article  CAS  PubMed  Google Scholar 

  14. Lu R, Sun X, Xiao R, Zhou L, Gao X, Guo L. Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility. Biochem Biophys Res Commun. 2012;419:274–80.

    Article  CAS  PubMed  Google Scholar 

  15. Granato T, Porpora MG, Longo F, Angeloni A, Manganaro L, Anastasi E. HE4 in the differential diagnosis of ovarian masses. Clin Chim Acta. 2015;446:147–55.

    Article  CAS  PubMed  Google Scholar 

  16. Holcomb K, Vucetic Z, Miller MC, Knapp RC. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. Am J Obstet Gynecol. 2011;205:358.e1–6.

    Article  CAS  Google Scholar 

  17. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108:402–8.

    Article  CAS  PubMed  Google Scholar 

  18. Anastasi E, Marchei GG, Viggiani V, Gennarini G, Frati L, Reale MG. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol. 2010;31:113–9.

    Article  CAS  PubMed  Google Scholar 

  19. Terry KL, Schock H, Fortner RT, Hüsing A, Fichorova RN, Yamamoto HS, et al. A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort. Clin Cancer Res. 2016. doi:10.1158/1078-0432.CCR-16-0316

  20. Zhang Y, Qiao C, Li L, Zhao X, Li Y. Serum HE4 is more suitable as a biomarker than CA125 in Chinese women with benign gynecologic disorders. Afr Health Sci. 2014;14(4):913–8.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Zhang Q, Wang CR, Yu JP, Ma Q, Xu WW. The establishment of an HE4-CLIA method and the combined analysis of HE4 and CA125 in ovarian cancer. J Clin Lab Anal. 2016. doi:10.1002/jcla.21926.

    Google Scholar 

  22. Fawzy A, Mohamed MR, Ali MA, Abd MA, El-Magied MH, Helal AM. Tissue CA125 and HE4 gene expression levels offer superior accuracy in discriminating benign from malignant pelvic masses. Asian Pac J Cancer Prev. 2016;17:323–33.

    Article  PubMed  Google Scholar 

  23. Chen X, Zhou H, Chen R, He J, Wang Y, Huang L, et al. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses. Clin Chim Acta. 2015;440:57–63.

    Article  CAS  PubMed  Google Scholar 

  24. Romagnolo C, Leon AE, Fabricio AS, Taborelli M, Polesel J, Del Pup L, et al. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: an Italian multicenter study. Gynecol Oncol. 2016;141:303–11.

    Article  CAS  PubMed  Google Scholar 

  25. Presl J, Kučera R, Topolčan O, Novotný Z, Vrzalová J, Fuchsova R, et al. HE4 a biomarker of ovarian cancer. Ceska Gynekol. 2012;77:445–9.

    CAS  PubMed  Google Scholar 

  26. Angioli R, Plotti F, Capriglione S, Montera R, Damiani P, Ricciardi R, et al. The role of novel biomarker HE4 in endometrial cancer: a case control prospective study. Tumour Biol. 2013;34:571–6.

    Article  CAS  PubMed  Google Scholar 

  27. Schummer M, Drescher C, Forrest R, Gough S, Thorpe J, Hellström I, et al. Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. Gynecol Oncol. 2012;125:65–9.

    Article  CAS  PubMed  Google Scholar 

  28. Plotti F, Capriglione S, Terranova C, Montera R, Aloisi A, Damiani P, et al. Does HE4 have a role as biomarker in the recurrence of ovarian cancer? Tumour Biol. 2012;33:2117–23.

    Article  CAS  PubMed  Google Scholar 

  29. Jiang J, Bo D, Chang X, Cheng H, Ye X, Cui H. Discrepant clinicopathologic characteristics and HE4 performance in type I and type II epithelial ovarian cancer. Int J Clin Exp Med. 2015;8:21303–10.

    PubMed  PubMed Central  Google Scholar 

  30. Wilailak S, Chan KK, Chen CA, Nam JH, Ochiai K, Aw TC, et al. Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings. J Gynecol Oncol. 2015;26:46–53.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, School of Medicine, Ondokuz Mayis University, 55200, Samsun, Turkey

    Mesut Onal, Erdal Malatyalioglu, Emel Kurtoglu Ozdes, Handan Celik, Migraci Tosun, Fatma Devran Bildircin, Tayfun Alper, Mehmet Bilge Cetinkaya & Arif Kokcu

  2. Department of Medical Microbiology, Ondokuz Mayis University, Samsun, Turkey

    Keramettin Yanik

Authors
  1. Mesut Onal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erdal Malatyalioglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Emel Kurtoglu Ozdes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Handan Celik
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Keramettin Yanik
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Migraci Tosun
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Fatma Devran Bildircin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tayfun Alper
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mehmet Bilge Cetinkaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Arif Kokcu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emel Kurtoglu Ozdes.

Ethics declarations

Conflict of interest

The authors declare that there are no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Onal, M., Malatyalioglu, E., Kurtoglu Ozdes, E. et al. Diagnostic Value of HE4 in Distinguishing Malignant from Benign Pelvic Masses. Indian J Gynecol Oncolog 14, 51 (2016). https://doi.org/10.1007/s40944-016-0079-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s40944-016-0079-8

Keywords

Search

Navigation